Aberrantly expressed mRNAs and long non-coding RNAs in patients with invasive ductal breast carcinoma: A pilot study

Chen,Xuedong; Yang,Jingyun; Qian,Liyuan; Cao,Tianzhu

doi:10.3892/mmr.2014.2989

Aberrantly expressed mRNAs and long non-coding RNAs in patients with invasive ductal breast carcinoma: A pilot study

Authors:
- Xuedong Chen
- Jingyun Yang
- Liyuan Qian
- Tianzhu Cao
View Affiliations

Affiliations: Department of Breast and Thyroid Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China, Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA
Published online on: November 20, 2014 https://doi.org/10.3892/mmr.2014.2989
Pages: 2185-2190

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Invasive ductal breast carcinoma (IDBC) is the most prevalent type of invasive breast cancer in females; however, the pathogenesis of IDBC remains to be elucidated. Therefore, the identification of novel markers may enhance current understanding of the initiation and development of IDBC as well as elucidate potential therapeutic targets for effective treatment of IDBC. In the present study, a pilot study was conducted to screen for potential mRNAs and long non‑coding (lnc)RNAs that exhibit aberrantly altered expression in patients with IDBC. Fresh breast cancer specimens and normal breast tissues were obtained from three female patients with IDBC aged ≥60 years following a modified radical mastectomy without chemotherapy. Expression levels of 44,244 probes were detected and included in the analysis, of which 22,078 (49.9%) were mRNAs and 22,166 (50.1%) were lncRNAs. Potential marker screening was performed using paired t‑tests (criterion 1), false discovery rates (FDR; criterion 2) and sure independence screening procedures based on distance correlations (DC‑SIS; criterion 3). The results showed that in IDBC tissues 3,510 probes had a ≥2‑fold statistically significant change in expression levels compared to those in the corresponding normal breast tissue (P<0.05); in addition, following FDR analysis, 353 probes were found to have significantly altered expression levels. Furthermore, DC‑SIS analysis identified 18 probes (12 mRNA and 6 lncRNAs) with significantly altered expression levels in IDBC tissue; these 18 probes therefore demonstrated significant results in all three criteria. Several of the mRNAs identified have been previously reported to be involved in signal transduction, protein binding, and cancer pathways, and the present study revealed that the majority of their gene products were located in the cytoplasm. Two of the six identified lncRNAs demonstrated a >10‑fold decrease in expression levels in IDBC tissues compared to that in the normal breast tissue. However, further studies are required in order to elucidate the biological functions of the identified probes.

View Figures

View References

1	Malhotra GK, Zhao X, Band H and Band V: Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther. 10:955–960. 2010. View Article : Google Scholar : PubMed/NCBI
2	Carter CL, Corle DK, Micozzi MS, Schatzkin A and Taylor PR: A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol. 128:467–477. 1988.PubMed/NCBI
3	Wiechmann L and Kuerer HM: The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer. 112:2130–2142. 2008. View Article : Google Scholar : PubMed/NCBI
4	Lakhani SR, Chaggar R, Davies S, et al: Genetic alterations in ‘normal’ luminal and myoepithelial cells of the breast. J Pathol. 189:496–503. 1999. View Article : Google Scholar
5	Yu KD, Wu LM, Liu GY, et al: Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. Ann Surg Oncol. 18:1342–1348. 2011. View Article : Google Scholar
6	Buerger H, Mommers EC, Littmann R, et al: Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol. 194:165–170. 2001. View Article : Google Scholar : PubMed/NCBI
7	Dziegiel P, Owczarek T, Plazuk E, et al: Ceramide galactosyltransferase (UGT8) is a molecular marker of breast cancer malignancy and lung metastases. Br J Cancer. 103:524–531. 2010. View Article : Google Scholar : PubMed/NCBI
8	Eswaran J, Cyanam D, Mudvari P, et al: Transcriptomic landscape of breast cancers through mRNA sequencing. Sci Rep. 2:2642012. View Article : Google Scholar : PubMed/NCBI
9	Gonçalves A, Finetti P, Sabatier R, et al: Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat. 127:273–281. 2011. View Article : Google Scholar
10	Volinia S and Croce CM: Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci USA. 110:7413–7417. 2013. View Article : Google Scholar : PubMed/NCBI
11	Gibb EA, Vucic EA, Enfield KS, et al: Human cancer long non-coding RNA transcriptomes. PloS One. 6:e259152011. View Article : Google Scholar : PubMed/NCBI
12	Ji P, Diederichs S, Wang W, et al: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 22:8031–8041. 2003. View Article : Google Scholar : PubMed/NCBI
13	Wan LB and Bartolomei MS: Regulation of imprinting in clusters: noncoding RNAs versus insulators. Adv Genet. 61:207–223. 2008. View Article : Google Scholar : PubMed/NCBI
14	Kung JT, Colognori D and Lee JT: Long noncoding RNAs: past, present, and future. Genetics. 193:651–669. 2013. View Article : Google Scholar : PubMed/NCBI
15	Gupta RA, Shah N, Wang KC, et al: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
16	Tsai MC, Manor O, Wan Y, et al: Long noncoding RNA as modular scaffold of histone modification complexes. Science. 329:689–693. 2010. View Article : Google Scholar : PubMed/NCBI
17	Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F and Williams GT: GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene. 28:195–208. 2009. View Article : Google Scholar
18	Bloom HJ and Richardson WW: Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 11:359–377. 1957. View Article : Google Scholar : PubMed/NCBI
19	Grimson A, Farh KK, Johnston WK, et al: MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI
20	Garcia DM, Baek D, Shin C, et al: Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol. 18:1139–1146. 2011. View Article : Google Scholar : PubMed/NCBI
21	Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
22	Huang da W, Sherman BT and Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37:1–13. 2009. View Article : Google Scholar :
23	Li R, Zhong W and Zhu L: Feature screening via distance correlation learning. J Am Stat Assoc. 107:1129–1139. 2012. View Article : Google Scholar : PubMed/NCBI
24	Bièche I, Chavey C, Andrieu C, et al: CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer. 14:1039–1052. 2007. View Article : Google Scholar : PubMed/NCBI
25	Acharyya S, Oskarsson T, Vanharanta S, et al: A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 150:165–178. 2012. View Article : Google Scholar : PubMed/NCBI
26	Rouleau M, Patel A, Hendzel MJ, Kaufmann SH and Poirier GG: PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 10:293–301. 2010. View Article : Google Scholar : PubMed/NCBI
27	Krupenko SA and Oleinik NV: 10-formyltetrahydrofolate dehydrogenase, one of the major folate enzymes, is down-regulated in tumor tissues and possesses suppressor effects on cancer cells. Cell Growth Differ. 13:227–236. 2002.PubMed/NCBI
28	Oleinik NV, Krupenko NI and Krupenko SA: Epigenetic Silencing of ALDH1L1, a Metabolic Regulator of Cellular Proliferation, in Cancers. Genes Cancer. 2:130–139. 2011. View Article : Google Scholar : PubMed/NCBI
29	Rinn JL, Kertesz M, Wang JK, et al: Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 129:1311–1323. 2007. View Article : Google Scholar : PubMed/NCBI
30	Lu L, Zhu G, Zhang C, et al: Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer. Breast Cancer Res Treat. 136:875–883. 2012. View Article : Google Scholar : PubMed/NCBI
31	Bernatsky S, Ramsey-Goldman R, Foulkes WD, Gordon C and Clarke AE: Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J Cancer. 104:1478–1481. 2011. View Article : Google Scholar : PubMed/NCBI
32	Tessier Cloutier B, Clarke AE, Ramsey-Goldman R, et al: Breast cancer in systemic lupus erythematosus. Oncology. 85:117–121. 2013. View Article : Google Scholar : PubMed/NCBI
33	Bernatsky S, Easton DF, Dunning A, et al: Decreased breast cancer risk in systemic lupus erythematosus: the search for a genetic basis continues. Lupus. 21:896–899. 2012. View Article : Google Scholar : PubMed/NCBI
34	Belot A, Kasher PR, Trotter EW, et al: Protein kinase cdelta deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis Rheum. 65:2161–2171. 2013. View Article : Google Scholar : PubMed/NCBI